| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 15.26 | 0.00 (0.00%) | 13.87 - 29.37 | 9.8 thousand (Below Avg) |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 15.26 |
| Day's Range | -- - -- |
| Market Cap | 752.4M |
| Avg Volume (10 Day) | 745.6K |
| Price/Earnings (Trailing 12 Mo.) | 9.5x |
| Earnings Per Share (Trailing 12 Mo.) | 1.61 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
PR Newswire - Wednesday 05/15/2013 7:00 AM ET
Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
PR Newswire - Friday 05/10/2013 4:43 PM ET
GTCR Announces Sale of Actient to Auxilium Pharmaceuticals
Business Wire - Monday 04/29/2013 7:26 AM ET
Auxilium Pharmaceuticals, Inc, Announces First Quarter 2013 Financial Results
PR Newswire - Monday 04/29/2013 7:00 AM ET
Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
PR Newswire - Monday 04/29/2013 7:00 AM ET
Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
PR Newswire - Thursday 04/25/2013 4:27 PM ET
| AUXL | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 38.74% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 10.53% | |
| Price/Sales | 1.94 |
| Company | Last | Change |
|---|---|---|
| USANA Health Sciences Inc | 68.51 | 0.00% |
| LifeVantage Corp | 2.36 | 0.00% |
| Nature's Sunshine Products Inc | 15.44 | 0.00% |
| Natural Alternatives International Inc | 4.60 | -1.71% |
| Cyanotech Corp | 5.77 | 0.00% |
Data is delayed by at least 15 min.